Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News

Latest news

ELCC: Phase I study of CO-1686 in patients with EGFR mutated recurrent, advanced NSCLC

31 Mar 2014
ELCC: Phase I study of CO-1686 in patients with EGFR mutated recurrent, advanced NSCLC

Evaluation of an irreversible, mutant-selective inhibitor of EGFR mutations

CO-1686 has demonstrated a good tolerability and promising efficacy against T790M epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC).

To read the rest of this story visit the ESMO site.

Related News

Performance in physical tests can help manage treatment for metastatic lung cancer 23 Oct 2024
Long-lasting immunotherapy response in stage IV lung cancer with brain metastasis 21 Oct 2024
Neural network models based on clinical characteristics for predicting immunotherapy efficacy in small cell lung cancer 14 Oct 2024
Researchers find ‘natural killer’ cells that live in the lung are ready for a sugar rush 11 Oct 2024
Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer 10 Oct 2024
Scientists discover that special immune cells stop metastatic cancer 9 Oct 2024
Drug improves effectiveness of radiation for lung cancer that has spread to the brain 8 Oct 2024
Faster, more sensitive lung cancer detection from a blood draw 4 Oct 2024
New insights on single-fraction radiation for central lung tumours 4 Oct 2024
The Lancet Public Health: Banning tobacco sales among young people could prevent 1.2 million lung cancer deaths, global modelling study suggests 3 Oct 2024

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation